436 related articles for article (PubMed ID: 32028615)
1. Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences.
Criscuolo M; Trecarichi EM
Antibiotics (Basel); 2020 Feb; 9(2):. PubMed ID: 32028615
[TBL] [Abstract][Full Text] [Related]
2. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Liscio JL; Mahoney MV; Hirsch EB
Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
[TBL] [Abstract][Full Text] [Related]
3. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
4. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.
van Duin D; Bonomo RA
Clin Infect Dis; 2016 Jul; 63(2):234-41. PubMed ID: 27098166
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
[TBL] [Abstract][Full Text] [Related]
6. Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study.
Cultrera R; Libanore M; Barozzi A; d'Anchera E; Romanini L; Fabbian F; De Motoli F; Quarta B; Stefanati A; Bolognesi N; Gabutti G
Antibiotics (Basel); 2020 Sep; 9(10):. PubMed ID: 32987821
[TBL] [Abstract][Full Text] [Related]
7. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Shields RK; Clancy CJ; Pasculle AW; Press EG; Haidar G; Hao B; Chen L; Kreiswirth BN; Nguyen MH
J Clin Microbiol; 2018 Feb; 56(2):. PubMed ID: 29167294
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
9. Association of
Sid Ahmed MA; Khan FA; Hadi HA; Skariah S; Sultan AA; Salam A; Al Khal AL; Söderquist B; Ibrahim EB; Omrani AS; Jass J
Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203733
[TBL] [Abstract][Full Text] [Related]
10. Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by
Daikos GL; da Cunha CA; Rossolini GM; Stone GG; Baillon-Plot N; Tawadrous M; Irani P
Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572708
[No Abstract] [Full Text] [Related]
11. Clinical outcomes of intensive care unit patients infected with multidrug-resistant gram-negative bacteria treated with ceftazidime/avibactam and ceftolozane/tazobactam.
Neves CS; Moura LCRV; Da Costa Lima JL; Maciel MAV
Braz J Microbiol; 2024 Mar; 55(1):333-341. PubMed ID: 38133795
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the
Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
[No Abstract] [Full Text] [Related]
13. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Grupper M; Sutherland C; Nicolau DP
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
[TBL] [Abstract][Full Text] [Related]
15. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.
Rodriguez BA; Girotto JE; Nicolau DP
Curr Pediatr Rev; 2018; 14(2):97-109. PubMed ID: 29521242
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
Sader HS; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
[TBL] [Abstract][Full Text] [Related]
17. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
[TBL] [Abstract][Full Text] [Related]
18. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
